The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Race Oncology (RAC) is set to expand its BISECT cancer trial for its Zantrene product to include five additional trial sites in Spain and Italy
  • With the extra trial sites, Race has signed a new clinical support agreement with Parexel International to support the necessary additional monitoring activities
  • The BISECT trial is testing Race’s Zantrene drug on extramedullary Acute Myeloid Leukaemia (EMD AML) and Myelodysplastic Syndromes (MDS)
  • Race is expecting the overall study to cost between $7.7 million to $15.4 million, depending on the location and number of patients that are enrolled
  • Shares in Race Oncology are up 3.66 per cent and trading at $1.70 per share at 12:55 pm AEST

Race Oncology (RAC) has agreed to expand its BISECT cancer trial for its lead Zantrene product to include five additional trial sites in Spain and Italy.

With the extra trial sites, Race has signed a new clinical support agreement with a global research organisation, Parexel International, to support additional necessary trial monitoring activities.

The BISECT trial is testing Zantrene drug on extramedullary Acute Myeloid
Leukaemia (EMD AML) and Myelodysplastic Syndromes (MDS).

Race Chief Medical Officer David Fuller said the company was pleased with the strong support for its BISECT trial from European haematologists.

“These clinicians identify a significant unmet need for the treatment of EMD AML and MDS and want to be actively involved in EMD clinical research,” Dr Fuller said.

“We look forward to activating these sites once we have cleared the necessary European Regulatory and Ethics approval process.”

EMD AML is when leukaemia cells spread from bone marrow and form a solid tumour in other tissues like the skin, breast, brain, or other organs. MDS are a group of blood cancers that all affect the production of normal blood cells in the bone marrow.

The company commenced patient recruitment in April at the Calvary Mater Hospital Newcastle.

Race is expecting the overall study to cost between $7.7 million to $15.4 million, depending on the location and number of patients that are enrolled and screened in the trial.

Shares in Race Oncology were up 3.66 per cent and trading at $1.70 per share at 12:55 pm AEST.

RAC by the numbers
More From The Market Online

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…